Caroline Young bought $429 of CPIX
director at CUMBERLAND PHARMACEUTICALS INC. 84 shares at an average of $5.11, traded May 1, 2025, filed Jun 6, 2025.
Score components
- +15RoleDirector
- 0Trade size$429 at market
- -5Relative to holdingsUnder 1% of holdings (0.3%)
- +4Price context29% below the 52-week high
- +15Cluster4 insiders buying within 14 days
- +5Repeat buying3 buys in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
- -1510b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -45.9%, 3m -43.1%, 6m -58.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-029852, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 1, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $4.86 | $19 | 32,489 | Jun 6, 2025 |
| May 2, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $4.75 | $19 | 32,493 | Jun 6, 2025 |
| May 5, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $4.68 | $19 | 32,497 | Jun 6, 2025 |
| May 6, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $4.60 | $18 | 32,501 | Jun 6, 2025 |
| May 7, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $4.71 | $19 | 32,505 | Jun 6, 2025 |
| May 8, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $4.50 | $18 | 32,509 | Jun 6, 2025 |
| May 9, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $4.78 | $19 | 32,513 | Jun 6, 2025 |
| May 12, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $5.25 | $21 | 32,517 | Jun 6, 2025 |
| May 13, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $5.67 | $23 | 32,521 | Jun 6, 2025 |
| May 14, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $5.68 | $23 | 32,525 | Jun 6, 2025 |
| May 15, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $5.20 | $21 | 32,529 | Jun 6, 2025 |
| May 16, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $5.37 | $21 | 32,533 | Jun 6, 2025 |
| May 19, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $4.92 | $20 | 32,537 | Jun 6, 2025 |
| May 20, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $5.41 | $22 | 32,541 | Jun 6, 2025 |
| May 21, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $5.05 | $20 | 32,545 | Jun 6, 2025 |
| May 22, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $5.10 | $20 | 32,549 | Jun 6, 2025 |
| May 23, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $5.14 | $21 | 32,553 | Jun 6, 2025 |
| May 27, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $5.27 | $21 | 32,557 | Jun 6, 2025 |
| May 28, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $5.68 | $23 | 32,561 | Jun 6, 2025 |
| May 29, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $5.66 | $23 | 32,565 | Jun 6, 2025 |
| May 30, 2025 | POpen-market purchase Common Stock10b5-1 | +4 | $4.93 | $20 | 32,569 | Jun 6, 2025 |
Related signals
Other insiders at CUMBERLAND PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $4,516 1,372 shares | +0% | |
| 33Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $862 262 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | James Jones director | $862 262 shares | +1% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Caroline Young director | $398 121 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $5,872 1,712 shares | +1% | |
| 33Weak | CUMBERLAND PHARMACEUTICALS INC | A J Kazimi Chairman and CEO | $1,166 340 shares | +0% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | James Jones director | $1,166 340 shares | +1% | |
| 23Weak | CUMBERLAND PHARMACEUTICALS INC | Caroline Young director | $578 168 shares | +1% | |
| 19Weak | CUMBERLAND PHARMACEUTICALS INC | Kenneth Krogulski director | $4,513 935 shares | +0% | |
| 19Weak | CUMBERLAND PHARMACEUTICALS INC | James Jones director | $807 168 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.